PL2182981T3 - Sposoby i kompozycje do leczenia i diagnozowania zwłóknienia - Google Patents

Sposoby i kompozycje do leczenia i diagnozowania zwłóknienia

Info

Publication number
PL2182981T3
PL2182981T3 PL08795003T PL08795003T PL2182981T3 PL 2182981 T3 PL2182981 T3 PL 2182981T3 PL 08795003 T PL08795003 T PL 08795003T PL 08795003 T PL08795003 T PL 08795003T PL 2182981 T3 PL2182981 T3 PL 2182981T3
Authority
PL
Poland
Prior art keywords
fibrosis
diagnosis
compositions
treatment
methods
Prior art date
Application number
PL08795003T
Other languages
English (en)
Polish (pl)
Inventor
Victoria Smith
Scott Ogg
Vlasselaer Peter Van
Vivian E Barry
Derek Marshall
Alison Kay Holzer
Hector Rodriguez
Miho Oyasu
Scott Alan Mccauley
Carlos Aurelio Garcia
Donna Hiroko Tokuoka Biermann
Original Assignee
Gilead Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Biologics Inc filed Critical Gilead Biologics Inc
Publication of PL2182981T3 publication Critical patent/PL2182981T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/5752—
    • G01N33/57525—
    • G01N33/5758—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
    • G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
PL08795003T 2007-08-02 2008-08-01 Sposoby i kompozycje do leczenia i diagnozowania zwłóknienia PL2182981T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US96328207P 2007-08-02 2007-08-02
US96324607P 2007-08-02 2007-08-02
US96324907P 2007-08-02 2007-08-02
US96324807P 2007-08-02 2007-08-02
US96321407P 2007-08-02 2007-08-02
PCT/US2008/009354 WO2009017833A2 (en) 2007-08-02 2008-08-01 Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
EP08795003A EP2182981B1 (en) 2007-08-02 2008-08-01 Methods and compositions for treatment and diagnosis of fibrosis

Publications (1)

Publication Number Publication Date
PL2182981T3 true PL2182981T3 (pl) 2013-06-28

Family

ID=40094743

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08795003T PL2182981T3 (pl) 2007-08-02 2008-08-01 Sposoby i kompozycje do leczenia i diagnozowania zwłóknienia
PL08830207T PL2185198T3 (pl) 2007-08-02 2008-08-01 Inhibitory LOX i L0XL2 oraz ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL08830207T PL2185198T3 (pl) 2007-08-02 2008-08-01 Inhibitory LOX i L0XL2 oraz ich zastosowania

Country Status (15)

Country Link
US (10) US8461303B2 (enExample)
EP (4) EP2185198B1 (enExample)
JP (8) JP5659014B2 (enExample)
CN (6) CN105330743B (enExample)
AU (4) AU2008299784B9 (enExample)
CA (2) CA2693310C (enExample)
CY (2) CY1113897T1 (enExample)
DK (2) DK2185198T3 (enExample)
ES (3) ES2402334T3 (enExample)
HR (2) HRP20130287T1 (enExample)
HU (1) HUE025283T2 (enExample)
PL (2) PL2182981T3 (enExample)
PT (3) PT2182981E (enExample)
SI (2) SI2182981T1 (enExample)
WO (2) WO2009035791A1 (enExample)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2896693B2 (ja) 1990-05-15 1999-05-31 高田重工株式会社 橋桁材の歪矯正装置
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
EP2185198B1 (en) * 2007-08-02 2015-01-14 Gilead Biologics, Inc. Lox and l0xl2 inhibitors and uses thereof
DK2268604T3 (en) * 2008-03-14 2017-03-27 Retrotope Inc CANCER THERAPIES BY USING ISOTO-SUBSTITUTED LYSIN
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
BRPI1007929A2 (pt) * 2009-02-06 2015-09-01 Arresto Biosciences Inc "métodos e composições para o tratamento de neovascularização".
EP2401613A2 (en) * 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20120122720A1 (en) 2009-05-05 2012-05-17 Yeda Research & Development Co. Ltd. Means and methods for recognizing the development of cardiovascular disease in an individual
CA2771774A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. In vitro screening assays
MX2012002269A (es) * 2009-08-21 2012-07-20 Gilead Biologics Inc Metodos y composiciones para el tratamiento de trastornos fibroticos pulmonares.
CN102711821A (zh) * 2009-08-21 2012-10-03 吉联亚生物科技有限公司 治疗方法和组合物
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
JP2013502226A (ja) * 2009-08-21 2013-01-24 ギリアド バイオロジクス，インク． リシル酸化酵素及びｌｏｘｌ２由来の触媒ドメイン
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
US20110076285A1 (en) * 2009-09-29 2011-03-31 Ingeborg Stalmans Methods and Compositions For Treatment of Ocular Fibrosis
DK2493296T3 (en) 2009-10-30 2019-04-15 Retrotope Inc REMOVAL OF OXIDATIVE STRESS STATES WITH PUFA DERIVATIVES
EP2528619B1 (en) 2010-01-26 2013-12-04 Centre Leon Berard Screening method for identifying compounds which block tumour growth by inducing irreversible senescence in tumour cells
CN103370080A (zh) * 2010-02-04 2013-10-23 吉联亚生物科技有限公司 结合赖氨酰氧化酶样2（loxl2）的抗体和其使用方法
AU2014215963B2 (en) * 2010-02-04 2016-04-14 Gilead Biologics, Inc Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
US20120329061A1 (en) * 2010-03-11 2012-12-27 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of cancer patients
WO2011132085A2 (en) * 2010-04-21 2011-10-27 Kalluri, Raghu Methods and compositions for treating fibrosis
CN105148269A (zh) 2011-02-21 2015-12-16 菲布他丁有限合伙公司 治疗和诊断疾病的方法
US20140186340A1 (en) * 2011-04-08 2014-07-03 Gilead Biologics, Inc. Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
WO2012148930A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
EP2701696B1 (en) 2011-04-26 2020-06-03 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
KR102020611B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환
KR102110175B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 Ｐｕｆａ 산화와 관련된 장애
WO2012155071A1 (en) * 2011-05-12 2012-11-15 Gilead Biologics, Inc. Methods of identifying lysyl oxidase - like - 2 (loxl2) binding partners
TW201319572A (zh) * 2011-06-01 2013-05-16 Gilead Biologics Inc 類氨醯氧化酶樣2(lysyl oxidase-like 2)測定及其使用方法
FR2976587B1 (fr) 2011-06-20 2015-04-03 Basf Beauty Care Solutions F Methode de dosage in vitro par technique immunologique
SG10201607331WA (en) * 2011-09-30 2016-11-29 Somalogic Inc Cardiovascular risk event prediction and uses thereof
CN102397544A (zh) * 2011-11-25 2012-04-04 百泰生物药业有限公司 一种单克隆抗体用于治疗非小细胞肺癌的用途
AU2013203619B2 (en) 2012-02-29 2015-02-26 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
EP2901163B1 (en) * 2012-09-28 2018-11-28 Case Western Reserve University Method for detecting lysyl oxidase-like 2 protein (loxl2) and breast cancer
AU2013337908A1 (en) 2012-10-30 2015-04-30 Gilead Sciences, Inc. Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (LOXL2)
WO2014152122A2 (en) * 2013-03-15 2014-09-25 Children's Medical Center Corporation Methods of altering vascular permeability and uses thereof
CN105358175B (zh) * 2013-05-23 2020-10-16 夏尔人类遗传性治疗公司 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
US20160331754A1 (en) 2014-01-20 2016-11-17 Gilead Sciences, Inc. Therapies for treating cancers
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
WO2015187499A1 (en) 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
KR20170018383A (ko) * 2014-06-11 2017-02-17 길리애드 사이언시즈, 인코포레이티드 심혈관 질환의 치료 방법
WO2016012993A1 (en) * 2014-07-24 2016-01-28 Yeda Research And Development Co. Ltd. Antibodies targeted against loxl-2 for the treatment of collagen-associated pathologies
EP2990480A1 (en) * 2014-08-29 2016-03-02 Christian-Albrechts-Universität zu Kiel Anti-LOXL4 antibodies and derivatives there
CA2968352A1 (en) 2014-12-08 2016-06-16 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
US10806787B2 (en) 2015-02-16 2020-10-20 Pharma Foods International Co., Ltd. Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof
AU2016216673B2 (en) 2015-03-04 2017-02-02 Gilead Sciences, Inc. Toll like receptor modulator compounds
ES2872553T3 (es) 2015-03-06 2021-11-02 Pharmakea Inc Inhibidores de lisil oxidasa tipo-2 y usos de los mismos
AU2016229268B2 (en) 2015-03-06 2020-09-10 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
CN106442956A (zh) * 2015-08-11 2017-02-22 钱朝南 一种筛选抗肿瘤转移的化合物的方法
WO2017049307A1 (en) 2015-09-17 2017-03-23 Ohio State Innovation Foundation Carborane compounds and methods of use thereof
US20190054090A1 (en) 2015-10-01 2019-02-21 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
AU2016361227B2 (en) 2015-11-23 2021-06-10 Biojiva Llc Site-specific isotopic labeling of 1, 4-diene systems
US10316049B2 (en) 2015-12-17 2019-06-11 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
CA3009445C (en) * 2016-02-03 2024-03-19 Nordic Bioscience A/S Combined biomarker measurement of fibrosis
EP3414226A4 (en) * 2016-02-12 2019-12-18 Pharmaxis Ltd. INDOL AND AZAINDOL HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYLOXIDASES AND USES THEREOF
GB201602934D0 (en) 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
AU2017228371A1 (en) 2016-03-04 2018-09-13 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
JP2019512271A (ja) 2016-03-21 2019-05-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用
US20190070145A1 (en) * 2016-03-22 2019-03-07 Mayo Foundation For Medical Education And Research Using fatty acid synthase inhibitors to treat fibrosis
JP2019513737A (ja) 2016-04-08 2019-05-30 ギリアード サイエンシーズ， インコーポレイテッド がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
WO2017181790A1 (zh) * 2016-04-19 2017-10-26 南京中硼联康医疗科技有限公司 用于消除β淀粉样蛋白沉积斑块的中子捕获治疗系统
WO2017197088A1 (en) * 2016-05-12 2017-11-16 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors for the treatment of inflammatory conditions
WO2017215590A1 (en) 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
EP3493797A1 (en) 2016-08-04 2019-06-12 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018048930A1 (en) * 2016-09-07 2018-03-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
MX390964B (es) 2016-09-07 2025-03-21 Pharmakea Inc Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion.
EP3509594B1 (en) 2016-09-07 2025-02-26 Pharmakea, Inc. A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
CN106492218A (zh) * 2016-11-08 2017-03-15 清华大学 氨基丙腈在制备药物中的用途
WO2018097977A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
KR20200108915A (ko) 2017-01-24 2020-09-21 아이-맵 바이오파마 유에스 리미티드 항-cd73 항체 및 이것의 사용
DE102017000896A1 (de) * 2017-02-01 2018-08-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Selektives Freisetzungssystem für Tumortherapeutika und Tumordiagnostika sowie Biosensor für Tumorgewebe
CN110312720A (zh) 2017-02-24 2019-10-08 吉利德科学公司 布鲁顿氏酪氨酸激酶的抑制剂
EP3585789A1 (en) 2017-02-24 2020-01-01 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
US10941178B2 (en) 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
US10632168B2 (en) 2017-04-06 2020-04-28 Sustain Holdings, Llc Collagen peptide-based medicament compositions and devices and methods of production and use thereof
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
KR102492187B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
IL275764B2 (en) * 2018-01-11 2023-11-01 Emphysema Solutions Bv Compositions and methods for the treatment of lung emphysema and other forms of copd
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
JP2021523151A (ja) 2018-05-11 2021-09-02 ホスホレックス、インコーポレイテッド 負の表面電荷を有するマイクロ粒子及びナノ粒子
EP4029868A1 (en) 2018-05-14 2022-07-20 Gilead Sciences, Inc. Mcl-1 inhibitors
MX2021000100A (es) 2018-07-13 2021-03-25 Gilead Sciences Inc Inhibidores de muerte programada-1 (pd-1)/ ligando de muerte programada 1 (pd-l1).
KR102780601B1 (ko) 2018-08-03 2025-03-12 파맥시스 엘티디 라이실 옥시다제의 할로알릴아민 설폰 유도체 저해제 및 이의 용도
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
HRP20240541T1 (hr) 2018-10-31 2024-07-05 Gilead Sciences, Inc. Supstituirani spojevi 6-azabenzimidazola kao inhibitori hpk1
WO2020101571A1 (en) * 2018-11-12 2020-05-22 Agency For Science, Technology And Research Methods for manipulating cell state transitions in cancer
WO2020117799A1 (en) * 2018-12-03 2020-06-11 Ohio State Innovation Foundation Carborane compounds, carborane analogs, and methods of use thereof
WO2020171199A1 (ja) * 2019-02-22 2020-08-27 コニカミノルタ株式会社 赤外発光化合物、それを含有する発光性薄膜、発光性粒子、波長変換膜及び赤外発光面光源
EP3705893A1 (en) * 2019-03-05 2020-09-09 Humanitas Mirasole S.p.A. Methods to assess the risk of being affected by prostate cancer
AU2020231115B2 (en) 2019-03-07 2025-02-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11389513B2 (en) 2019-04-22 2022-07-19 Sustain Holdings, Llc Collagen peptide-based medicament compositions and devices and methods of production and use thereof
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
FI20195550A1 (en) * 2019-06-20 2020-12-21 Kemira Oyj Risk level assessment in an aqueous process
US11446303B2 (en) * 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
KR102776925B1 (ko) 2019-06-25 2025-03-11 길리애드 사이언시즈, 인코포레이티드 Flt3l-fc 융합 단백질 및 사용 방법
US11697807B2 (en) 2019-09-30 2023-07-11 Case Western Reserve University Electrochemical biosensor
CN115103850B (zh) * 2019-10-15 2024-07-12 韩国巴斯德研究所 2-甲氧基雌二醇衍生物及其医学用途
CN111118142A (zh) * 2020-01-17 2020-05-08 上海市同济医院 血清赖氨酸氧化酶作为肾间质纤维化的分层诊断性生物标志物
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
TW202143994A (zh) 2020-02-19 2021-12-01 美商希皮恩製藥公司 環孢素類似物於治療纖維化之用途
IL321252A (en) 2020-02-21 2025-08-01 Retrotope Inc Processes for isotopic alteration of polyunsaturated fatty acids and their derivatives
CN115997122A (zh) 2020-06-26 2023-04-21 拉夸里亚创药株式会社 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物
GB202019109D0 (en) * 2020-12-03 2021-01-20 Novai Ltd Marker for use in identifying or predicting angiogenesis
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
CN113321743B (zh) * 2021-07-02 2022-10-21 海南精准医疗科技有限公司 一种靶向赖氨酰氧化酶1的嵌合抗原受体及其用途
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
JP2024546851A (ja) 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CR20240386A (es) 2022-03-17 2024-10-24 Gilead Sciences Inc Degradadores de dedos de zinc de la familia ikaros y usos de estos
US12233056B2 (en) 2022-04-06 2025-02-25 Syntara Limited Lysyl oxidase inhibitors for treating myeloid malignancies
AU2023256670A1 (en) 2022-04-21 2024-10-17 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023239764A1 (en) * 2022-06-08 2023-12-14 Ohio State Innovation Foundation Methods and compositions for treating lupus
CA3260083A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. CD73 COMPOUNDS
CN116064765B (zh) * 2022-08-02 2023-09-05 首都医科大学附属北京友谊医院 检测loxl1基因突变的物质在制备肝纤维化患者分子分型的产品中的应用
AU2023357892A1 (en) * 2022-10-07 2025-05-22 Nanoegg Research Laboratories, Inc. Method for detecting inflammatory skin disease and judging severity thereof
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
AU2024259556A1 (en) 2023-04-21 2025-10-23 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
CN116794308A (zh) * 2023-07-20 2023-09-22 中国药科大学 β-1,4-半乳糖基转移酶1及其抑制剂在制备治疗急慢性肝病药物中的应用
TW202519517A (zh) 2023-07-26 2025-05-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN120518770B (zh) * 2025-05-21 2025-12-09 北京大学人民医院 一种抗loxl2纳米抗体或抗原结合片段与应用
CN120425051A (zh) * 2025-07-09 2025-08-05 吉林大学 Angpt2作为生物标志物在嗜铬细胞瘤和副神经节瘤分子分型及预后评估中的应用
CN120600339B (zh) * 2025-08-05 2025-09-30 中国人民解放军空军军医大学 一种抗真菌药物肝毒性检测方法及系统

Family Cites Families (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7002A (en) * 1850-01-08 Obe-washek
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) * 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) * 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) * 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) * 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) * 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) * 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) * 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
JPS5913521B2 (ja) 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US3984533A (en) * 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
JPS57501234A (enExample) * 1980-08-25 1982-07-15
US4879219A (en) * 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0078636B2 (en) 1981-10-23 1997-04-02 MediSense, Inc. Sensor for components of a liquid mixture
US4485088A (en) 1982-03-26 1984-11-27 Bio-Products, Inc. Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5011771A (en) * 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) * 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
PT81498B (pt) 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4627445A (en) 1985-04-08 1986-12-09 Garid, Inc. Glucose medical monitoring system
US4801531A (en) * 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US4916193A (en) 1987-12-17 1990-04-10 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) * 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021404A (en) 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5092877A (en) 1988-09-01 1992-03-03 Corvita Corporation Radially expandable endoprosthesis
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
CA2006008C (en) 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US4994071A (en) 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5262035A (en) 1989-08-02 1993-11-16 E. Heller And Company Enzyme electrodes
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5163952A (en) 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5641484A (en) 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
AT397134B (de) * 1991-02-19 1994-02-25 Hoerbiger Ventilwerke Ag Ventil
US6933286B2 (en) * 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US20020123476A1 (en) * 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US6235887B1 (en) * 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz, Joseph R. Phasenmodulationsenergieübertragungsfluoroimmunassay
US5281521A (en) * 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6015562A (en) * 1992-09-22 2000-01-18 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5721138A (en) * 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
FI92882C (fi) 1992-12-29 1995-01-10 Medix Biochemica Ab Oy Kertakäyttöinen testiliuska ja menetelmä sen valmistamiseksi
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5646185A (en) 1993-10-14 1997-07-08 The Board Of Trustees Of The Leland Stanford Junior University Tumor treatment method
US5674693A (en) 1994-03-18 1997-10-07 Natural Pharmacia International Inc. Derivatives of 2-nitro-imidazoles as hypoxic cell markers
US5700695A (en) 1994-06-30 1997-12-23 Zia Yassinzadeh Sample collection and manipulation method
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US6096716A (en) 1994-12-12 2000-08-01 The Board Of Regents, The University Of Texas System Liposome-mediated transfection of central nervous system cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5935860A (en) 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
US6120536A (en) 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
WO1996040746A1 (en) 1995-06-07 1996-12-19 Trustees Of Boston University Lysyloxidase inhibitors
AUPN363995A0 (en) 1995-06-19 1995-07-13 Memtec Limited Electrochemical cell
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
NO971448L (no) 1996-04-01 1997-10-02 Sankyo Co Rekombinante anti-Fas-antistoffer og DNA for disse
AUPO156596A0 (en) 1996-08-09 1996-09-05 University Of Sydney, The Synthetic polynucleotides
US6489093B1 (en) 1996-09-20 2002-12-03 President And Fellows Of Harvard College Combinatorial approach for generating novel coordination complexes
US5958703A (en) 1996-12-03 1999-09-28 Glaxo Group Limited Use of modified tethers in screening compound libraries
DE69809391T2 (de) * 1997-02-06 2003-07-10 Therasense, Inc. Kleinvolumiger sensor zur in-vitro bestimmung
AU6468998A (en) * 1997-03-19 1998-10-12 Board Of Trustees Of The University Of Arkansas, The Compositions and method for the early diagnosis of ovarian cancer
DK1504764T3 (da) * 1997-08-08 2008-11-17 Univ California Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin
US6277622B1 (en) 1997-08-11 2001-08-21 The University Of Sydney Synthetic polynucleotides
US6225118B1 (en) * 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
CA2308565A1 (en) * 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
US6300092B1 (en) 1999-01-27 2001-10-09 Millennium Pharmaceuticals Inc. Methods of use of a novel lysyl oxidase-related protein
US20020072089A1 (en) * 1999-11-23 2002-06-13 Holtzman Douglas A. Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor
US6140056A (en) * 1999-01-27 2000-10-31 Millennium Pharmaceuticals, Inc. MSP-18 protein and nucleic acid molecules and uses therefor
WO1999046385A2 (en) * 1998-03-13 1999-09-16 Baylor College Of Medicine Compositions and methods for the treatment and prevention of metastatic disorders
WO1999065928A2 (en) 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
US6228538B1 (en) * 1998-08-28 2001-05-08 Micron Technology, Inc. Mask forming methods and field emission display emitter mask forming methods
US20040058355A1 (en) * 1998-09-30 2004-03-25 Millennium Pharmaceuticals, Inc. Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
US20030149997A1 (en) 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
TR200200027T2 (tr) * 1999-04-22 2002-07-22 Biogen, Inc. İntergrin alfa-4 alt-biriminin bir antagonisti kullanılarak fibrozun tedavisi.
US20030152926A1 (en) 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
GB0001309D0 (en) * 2000-01-20 2000-03-08 Nestle Sa Valve arrangement
US6808707B2 (en) 2000-02-04 2004-10-26 Matrix Design Wound healing compositions and methods using tropoelastin and lysyl oxidase
CA2405781A1 (en) 2000-04-14 2001-10-25 Incyte Genomics, Inc. Secreted proteins
AU2001261194A1 (en) 2000-05-03 2001-11-12 University Of Hawaii Novel members of the lysyl oxidases family of amine oxidases related applications
AU2001265162A1 (en) 2000-05-26 2001-12-11 Millennium Pharmaceuticals, Inc. 47765, a novel human lysyl oxidase and uses thereof
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
GB0014185D0 (en) * 2000-06-09 2000-08-02 Novartis Res Found Compound and method
US20090233270A9 (en) 2000-08-02 2009-09-17 St Croix Brad Secreted and cytoplasmic tumor endothelial markers
ES2437093T3 (es) 2000-08-08 2014-01-08 Technion Research And Development Foundation, Ltd. Composiciones farmacéuticas y procedimientos útiles para modular la angiogénesis
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
ATE364087T1 (de) * 2000-08-08 2007-06-15 Wyeth Corp Regulierung der expression von eer-7, ein mitglied der lysyl oxidase genfamilie, durch oestrogenrezeptoren
US20020156263A1 (en) * 2000-10-05 2002-10-24 Huei-Mei Chen Genes expressed in breast cancer
EP1425412A2 (en) * 2000-11-28 2004-06-09 University Of Cincinnati Blood assessment of injury
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7112668B2 (en) 2001-01-23 2006-09-26 Curagen Corporation Polypeptides and nucleic acids encoded thereby
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2002061092A2 (en) 2001-01-29 2002-08-08 Bayer Aktiengesellschaft Regulation of human lysyl oxidase
JP2004531249A (ja) 2001-02-14 2004-10-14 プロテイン デザイン ラブス インコーポレイティド 血管新生の診断方法、組成物、及び血管新生モジュレータのスクリーニング方法
EP1404868A2 (en) 2001-02-28 2004-04-07 Chondrogene Inc. Compositions and methods relating to osteoarthritis
US20020182274A1 (en) * 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
EP1463928A2 (en) 2001-04-18 2004-10-06 Protein Design Labs Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US20030211076A1 (en) 2001-05-10 2003-11-13 Wande Li Compositions and methods for treatment of proliferative disorders
US20030092037A1 (en) 2001-07-18 2003-05-15 Osamu Matsuzaki Elk1 phosphorylation related gene
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US20030129672A1 (en) 2001-08-29 2003-07-10 Dyer Richard Dennis Method for identifying metalloenzyme inhibitors
WO2003031939A2 (en) 2001-10-12 2003-04-17 Incyte Genomics, Inc. Protein modification and maintenance molecules
JP2005506087A (ja) 2001-10-26 2005-03-03 リボファーマ アーゲー プラス鎖ｒｎａウイルスによる感染症を処置するための２本鎖リボ核酸の使用
KR100450950B1 (ko) * 2001-11-29 2004-10-02 삼성전자주식회사 구내/공중망 무선 패킷데이터 서비스를 받는 이동단말기의 인증 방법 및 그 사설망 시스템
EP1455813B1 (en) 2001-12-18 2015-07-15 mondoBIOTECH AG Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis
US7186540B2 (en) 2001-12-27 2007-03-06 National Institute of Advanced Indusrtial Science and Technology Thermostable glutaminase and thermostable glutaminase gene
WO2003080640A1 (en) 2002-03-07 2003-10-02 Ludwig Institute For Cancer Research Lymphatic and blood endothelial cell genes
US7655397B2 (en) 2002-04-25 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
WO2003100016A2 (en) 2002-05-22 2003-12-04 Incyte Corporation Protein modification and maintenance molecules
JP4753578B2 (ja) * 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
WO2004002427A2 (en) * 2002-06-27 2004-01-08 The General Hospital Corporation Methods for the treatment or prevention of obesity
EP2236614A3 (en) 2002-08-15 2011-01-26 Genzyme Corporation Brain endothelial cell expression patterns
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
CA2881743A1 (en) * 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20040156854A1 (en) 2002-12-06 2004-08-12 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
US20060188889A1 (en) 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
EP1581812B1 (en) 2003-01-06 2008-07-16 Wyeth Compositions and methods for diagnosing and treating colon cancers
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
AU2004218407A1 (en) * 2003-03-03 2004-09-16 Board Of Regents, The University Of Texas System Methods and compositions involving MDA-7
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
AT500650B1 (de) * 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
CA2524567A1 (en) 2003-05-23 2004-12-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumors of glial origin
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
FR2855968B1 (fr) * 2003-06-13 2012-11-30 Coletica Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques
FR2855969B1 (fr) 2003-06-13 2012-11-30 Coletica Stimulation de l'activite d'une isoforme de lysyl oxydase pour lutter contre certaines pathologies dues a une elastogenese incomplete, absente ou desorganisee
ATE511550T1 (de) * 2003-07-17 2011-06-15 Pacific Edge Biotechnology Ltd Marker zum nachweis von magenkrebs
EP1670494A1 (en) * 2003-09-16 2006-06-21 Hadasit Medical Research Services & Development Ltd. Glatiramer acetate for use as an immuno-modulatory agent
EP2311945A1 (en) * 2003-10-14 2011-04-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies substituting for functional proteins
JP4411280B2 (ja) 2003-10-20 2010-02-10 帝人ファーマ株式会社 骨及び／又は関節疾患関連遺伝子
US20070054278A1 (en) 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2005094424A2 (en) 2004-01-13 2005-10-13 Trustees Of Boston University Use of the pro-peptide domain of lysyl oxidase as a therapeutic agent
JP2007526247A (ja) 2004-01-23 2007-09-13 マサチューセッツ・アイ・アンド・イア・インファーマリー リジルオキシダーゼ様１（ｌｏｘｌ１）および弾性繊維形成
CN101088089A (zh) 2004-02-23 2007-12-12 鹿特丹伊拉斯姆斯大学医疗中心 通过基因表达图形对急性粒细胞性白血病进行分类、诊断和预后
EP1721010A2 (en) * 2004-02-24 2006-11-15 Attenuon, LLC Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
CA2561742A1 (en) 2004-04-01 2005-10-27 Sequenom, Inc. Methods for identifying risk of osteoarthritis and treatments thereof
JP5222559B2 (ja) * 2004-10-15 2013-06-26 シアトル ジェネティックス， インコーポレイテッド 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用
US20060134172A1 (en) 2004-12-21 2006-06-22 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2006086484A1 (en) * 2005-02-09 2006-08-17 Arqule, Inc. Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
JP4988606B2 (ja) * 2005-02-28 2012-08-01 サンガモ バイオサイエンシズ インコーポレイテッド 抗血管新生方法及び組成物
US20060216722A1 (en) 2005-03-25 2006-09-28 Christer Betsholtz Glomerular expression profiling
US9234897B2 (en) 2005-03-31 2016-01-12 Two Cells Co., Ltd Method for distinguishing mesenchymal stem cell using molecular marker and use thereof
WO2006108048A1 (en) * 2005-04-05 2006-10-12 The General Hospital Corporation Method for predicting responsiveness to drugs
WO2006128740A2 (en) 2005-06-02 2006-12-07 Centelion Anti-vascular methods and therapies employing lysyl oxidase inhibitors
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US20070021365A1 (en) 2005-06-21 2007-01-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US8158107B2 (en) * 2005-09-30 2012-04-17 National Jewish Health Genes and proteins associated with angiogenesis and uses thereof
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US20090035348A1 (en) 2005-11-22 2009-02-05 Z & Z Medical Holdings, Inc. Dissolution of arterial plaque
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
GB0524991D0 (en) 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
MY147217A (en) * 2005-12-09 2012-11-14 Ucb Pharma Sa Antibody molecules having specificity for human il-06
CA2639070A1 (en) 2006-04-13 2007-11-01 Oncomethylime Sciences S.A. Novel tumour suppressor
NZ572561A (en) 2006-06-07 2012-05-25 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
WO2008063479A2 (en) 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
US20100074897A1 (en) 2006-12-01 2010-03-25 University Of Utah Research Foundation Methods and Compositions related to HIF-1 alpha
US8077896B2 (en) 2006-12-12 2011-12-13 Sound Services, Llc Laser inclinometer audio direction
KR101443214B1 (ko) 2007-01-09 2014-09-24 삼성전자주식회사 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
WO2008138578A2 (en) 2007-05-11 2008-11-20 Medical Prognosis Institute Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8178091B2 (en) 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
EP3127549B1 (en) * 2007-06-22 2019-12-18 Children's Medical Center Corporation Methods and uses thereof of a fragment of saposin a
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
EP2185198B1 (en) * 2007-08-02 2015-01-14 Gilead Biologics, Inc. Lox and l0xl2 inhibitors and uses thereof
US8815946B2 (en) * 2008-01-25 2014-08-26 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of proliferation and fibrotic response of activated corneal stromal cells
JP2010038735A (ja) 2008-08-05 2010-02-18 Terumo Corp 腹膜機能の評価方法および腹膜機能評価用イムノクロマト試験紙
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
BRPI1007929A2 (pt) * 2009-02-06 2015-09-01 Arresto Biosciences Inc "métodos e composições para o tratamento de neovascularização".
JP2013502226A (ja) * 2009-08-21 2013-01-24 ギリアド バイオロジクス，インク． リシル酸化酵素及びｌｏｘｌ２由来の触媒ドメイン
MX2012002269A (es) 2009-08-21 2012-07-20 Gilead Biologics Inc Metodos y composiciones para el tratamiento de trastornos fibroticos pulmonares.
WO2011022670A1 (en) 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
CA2771774A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. In vitro screening assays
CN102711821A (zh) 2009-08-21 2012-10-03 吉联亚生物科技有限公司 治疗方法和组合物
US20110076285A1 (en) * 2009-09-29 2011-03-31 Ingeborg Stalmans Methods and Compositions For Treatment of Ocular Fibrosis
CN103370080A (zh) 2010-02-04 2013-10-23 吉联亚生物科技有限公司 结合赖氨酰氧化酶样2（loxl2）的抗体和其使用方法
US20140186340A1 (en) 2011-04-08 2014-07-03 Gilead Biologics, Inc. Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
TW201319572A (zh) 2011-06-01 2013-05-16 Gilead Biologics Inc 類氨醯氧化酶樣2(lysyl oxidase-like 2)測定及其使用方法
AU2013337908A1 (en) 2012-10-30 2015-04-30 Gilead Sciences, Inc. Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (LOXL2)
CA2893977C (en) * 2012-12-21 2024-02-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods

Also Published As

Publication number Publication date
US20130324705A1 (en) 2013-12-05
JP5659014B2 (ja) 2015-01-28
WO2009017833A8 (en) 2010-10-14
EP2537529A1 (en) 2012-12-26
AU2008299784B9 (en) 2015-06-18
ES2534490T3 (es) 2015-04-23
CA2693208A1 (en) 2009-02-05
DK2182981T3 (en) 2013-04-02
CN110372795A (zh) 2019-10-25
CA2693310A1 (en) 2009-03-19
JP2010535205A (ja) 2010-11-18
WO2009017833A2 (en) 2009-02-05
PT2182981E (pt) 2013-04-18
JP2013231035A (ja) 2013-11-14
HK1143736A1 (en) 2011-01-14
US20140349309A1 (en) 2014-11-27
US20140079707A1 (en) 2014-03-20
EP2185198A1 (en) 2010-05-19
WO2009035791A1 (en) 2009-03-19
JP2010535219A (ja) 2010-11-18
PL2185198T3 (pl) 2015-06-30
US20120087917A1 (en) 2012-04-12
CY1113897T1 (el) 2016-07-27
CN105330743A (zh) 2016-02-17
DK2185198T3 (en) 2015-04-20
EP2182981A2 (en) 2010-05-12
AU2017200635B9 (en) 2019-04-18
AU2008282739B2 (en) 2013-12-19
CN101835490A (zh) 2010-09-15
AU2014204536A1 (en) 2014-08-07
US8658167B2 (en) 2014-02-25
US20130095101A1 (en) 2013-04-18
AU2008299784A1 (en) 2009-03-19
US20140128284A1 (en) 2014-05-08
PT2185198E (pt) 2015-04-20
WO2009017833A3 (en) 2009-06-25
HRP20150208T1 (hr) 2015-06-05
JP2017214361A (ja) 2017-12-07
US20160185877A1 (en) 2016-06-30
JP2018172398A (ja) 2018-11-08
EP2537529B1 (en) 2018-10-17
CA2693310C (en) 2018-11-27
CN105214085A (zh) 2016-01-06
AU2008299784B2 (en) 2014-04-24
AU2008299784A9 (en) 2015-06-18
US10494443B2 (en) 2019-12-03
WO2009035791A9 (en) 2014-06-26
JP5770219B2 (ja) 2015-08-26
ES2402334T3 (es) 2013-04-30
HK1143543A1 (en) 2011-01-07
ES2700141T3 (es) 2019-02-14
US20090053224A1 (en) 2009-02-26
US8461303B2 (en) 2013-06-11
US20170240649A1 (en) 2017-08-24
HRP20130287T1 (en) 2013-05-31
JP2016094428A (ja) 2016-05-26
JP2015212281A (ja) 2015-11-26
JP2014210785A (ja) 2014-11-13
SI2185198T1 (sl) 2015-04-30
US9176139B2 (en) 2015-11-03
US20090104201A1 (en) 2009-04-23
CN105622756A (zh) 2016-06-01
EP2182981B1 (en) 2013-01-09
AU2014204536B2 (en) 2016-12-01
SI2182981T1 (sl) 2013-05-31
CY1116178T1 (el) 2017-02-08
HUE025283T2 (en) 2016-03-29
JP5851555B2 (ja) 2016-02-03
AU2008282739A1 (en) 2009-02-05
US8679485B2 (en) 2014-03-25
CN105330743B (zh) 2019-05-28
EP2543389A3 (en) 2013-04-24
EP2543389A2 (en) 2013-01-09
CN105622756B (zh) 2020-07-28
JP6357264B2 (ja) 2018-07-11
PT2537529T (pt) 2018-12-12
EP2185198B1 (en) 2015-01-14
JP5312459B2 (ja) 2013-10-09
AU2017200635B2 (en) 2019-04-04
CN101842114A (zh) 2010-09-22
AU2017200635A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
SI2182981T1 (sl) Postopki in sestavki za zdravljenje in diagnozo fibroze
IL258730A (en) Preparations and methods for the treatment of microbial disorders
ZA201003028B (en) Methods and compositions for diagnosis and treatment of amyloidosis
GB201108374D0 (en) Compositions and methods for the treatment of altered synuclein function
EP2293800A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EARLIER DISEASES
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
PL2180783T3 (pl) Kompozycje i sposoby d o zaprawiania nasion
EP2482814A4 (en) METHOD AND COMPOSITIONS FOR TREATING OKULAR FIBROSIS
IL196465A0 (en) Compositions and methods for the treatment of mucositis
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
IL215856A0 (en) Compositions and methods for treatment of cardiovascular disease
GB0718446D0 (en) Compositions and methods for the treatment of infection
IL198723A0 (en) Methods and compositions for therapeutic treatment
EP2271352A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE
IL212353A0 (en) Compositions and methods for treatment of kidney disorders
EP2021005A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN
EP2328569A4 (en) COMPOSITIONS AND METHODS OF TREATMENT COMPRISING CEFTAROLINE
ZA201102207B (en) Cinnamandehyde-allicin compositions and their method of use
EP2147013A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DEPRESSION AND FEARING
IL211425A0 (en) Compositions and methods of treating amyloid disease
GB0608647D0 (en) Methods of diagnosis and treatment
GB0619500D0 (en) Treatment of fibrosis
ZA201107820B (en) Compositions and methods for treatment of aortic fibrosis
EP2480099A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES